Dr. Hyman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 646-888-4544
Summary
- I am a medical oncologist who specializes in the treatment of gynecologic cancers. My research interests including developmental therapeutics, gynecologic cancer, rare uterine sarcomas, and BRCA-associated ovarian cancer.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
Weill Cornell MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2007 - 2025
NJ State Medical License 2019 - 2021
Clinical Trials
- A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) Start of enrollment: 2010 Jul 01
- Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer Start of enrollment: 2010 Nov 01
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
- Join now to see all
Publications & Presentations
PubMed
- 1271 citationsA view on drug resistance in cancerNeil Vasan, José Baselga, David M. Hyman
Nature. 2019-11-13 - 980 citationsAACR project genie: Powering precision medicine through an international consortiumShawn M. Sweeney, Ethan Cerami, Alexander S. Baras, Trevor J. Pugh, Nikolaus Schultz
Cancer Discovery. 2017-01-01 - 302 citationsImplementing Genome-Driven OncologyDavid M. Hyman, Barry S. Taylor, José Baselga
Cell. 2017-02-09
Journal Articles
- Efficacy of MEK Inhibition in Patients with Histiocytic NeoplasmsRobert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
- Article Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerSarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
- Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancerHyman, D.M., Spriggs, D.R., JAMA
- Join now to see all
Abstracts/Posters
- Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor MalignancyClinically Relevant AbstractDavid M. Hyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.2019 ASCO Annual Meeting - 6/1/2019
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.2019 ASCO Annual Meeting - 6/1/2019
- Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Eli Lilly's Verzenio Snags First-in-Class FDA Approval for Early Breast Cancer. But Limited Label Poses a ChallengeOctober 13th, 2021- FDA Expands Lilly's ERBITUX® (Cetuximab) Label with Combination of BRAFTOVI® (Encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) After Prior TherapySeptember 28th, 2021
- Lilly Presents New Data on Retevmo® (Selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual MeetingApril 11th, 2021
- Join now to see all
Grant Support
- Young Investigator AwardKaleidoscope of Hope Foundation2011–Present
Committees
- Member, SEP Working Group, American Society of Clinical Oncology 2011 - Present
- Member, Investigational New Drug Committee, Memorial Sloan-Kettering Cancer Center 2011 - Present
- Member, Admissions Committee, Weill Cornell Medical College 2010 - Present
- Member, Organization of Resident Representatives, AAMC 2010 - Present
- Member, Fellow Advisory Group, American Society of Clinical Oncology 2009 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
